Cambridge, United Kingdom, October 15, 2011 --(PR.com
)-- ImmunoBiology Ltd, a vaccine R&D company based Babraham Research Campus near Cambridge, UK recently signed initial cooperation agreement with LIBP a subsidiary company under Sinopharm’s biological products division – CNBG (China National Biotech Group) with the close coordination by Cambridge based biopharma consultancy company –Link China Pharma Solutions.
This partnership collaboration will enable ImmBio and LIBP (Lanzhou Institute of Biological Product) to co-develop ImmBio’s proprietary T-Biovax vaccine for Tuberculosis (TB) into clinical studies in China aiming to launch the TB vaccine first into China market upon completion of successful clinical studies. This Sino-UK high-tech partnership deal first initiated nearly a year ago by Marshall Ma – Managing Director of Link China Pharma Solutions as ImmBio’s China Business Development personal. Over the course of the past year, ImmBio’s CEO Graham Clarke, CTO Chris Bailey and Marshall Ma had intensive business discussions and technical exchanges with CNBG President, Vice President, Chief Scientist and other top Chinese vaccine experts at CNBG headquarters in Beijing and in Lanzhou China.
The partnership will form a strategic alliance between ImmBio’s proprietary platform technology based innovative TB vaccine product with Chinese partner’s strong technical ability, manufacturing capacity and well established distribution channel in China vaccine market. This partnership will also lead the way for more successful collaboration opportunities on ImmBio’s ImmBioVax platform technology and ImmunoBodies platform technology based anti-infectious vaccines such as Meningitis, Pneumococcal, Hepatitis C and Flu vaccines etc.
Tuberculosis (TB) is a serious, debilitating and highly contagious disease affecting millions of people worldwide. If not properly treated, it is often fatal. TB is responsible for the greatest number of deaths from an infectious disease. Each year 54 million people are infected, 6.8 million develop clinical disease and 2.4 million people die of TB. It is endemic in numerous countries. Tuberculosis is a major public health problem in China. China has the world's second largest tuberculosis epidemic (after India), of the 37 notifiable communicable diseases in China, tuberculosis ranks first in terms of notified cases and deaths. Naturally prevention of TB infection becomes the Chinese government's top priority infectious disease control initiative. Therefore this TB vaccine partnership deal between Sino-UK companies will add its significance and will speed up the development process to produce an effective TB vaccine to fight the infection.
China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. Lanzhou Institute of Biological Products (LIBP) was founded in 1934 with a long history of 70 years and is a subsidiary company under Sinopharm’s Biological Product Arm - China National Biotech Corporation. LIBP is engaged in the R & D, manufacture and marketing of biological products. The main task of the Institute is researching, producing and selling biological products used for prevention, treatment and diagnosis of infectious diseases and other diseases. LIBP is selected as one of the industrialized basements of National 863 Program under the Ministry of Science & Technology and one of the Technique Centre of State Enterprises. Sinopharm.com
About ImmunoBiology Ltd
ImmunoBiology Ltd is a vaccine company developing the next generation of anti-infective vaccines. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe. ImmBio has an established product and process patent estate around Heat shock protein Complexes (ImmBioVax) which are highly efficient in bridging between an innate and an adaptive immunological response. In addition, ImmBio has licensed in complementary technology around the delivery of antigens to dendritic cells through fusion proteins (ImmunoBodies) in specific applications, where this approach has clear benefits. ImmBio has experienced executive and staff in its facilities in Cambridge (UK) and has built an impressive product portfolio backed by a solid and broad investor base and through collaborative agreements. Immbio.com
About Link China Pharma Solutions
Link China Pharma Solutions is a UK Cambridge based dedicated technology brokerage and services provider bringing in-depth China industry experience and market knowledge to provide a range of specialist services to promote research co-operation, technology transfer and business collaboration between China and UK/EU life science research institutes, biotech and pharmaceutical companies to maximize the value of research and business alliances. LCPS brings in-depth industry experience and global market knowledge to support UK/EU small, medium and large biopharmaceutical and life science companies to build the collaboration with Chinese partners and provide a full suite of services from strategy alignment, partnership selection, collaborative partnering, outsourcing transaction in drug discovery and development, clinical trial, contract manufacturing, to China market entry and development so that our clients can minimize the cost, gain the competitive advantage in the global market and place themselves well ahead to access one of the fastest growing pharmaceutical market in the world. Chinapharma.co.uk